Why the study?
Ischemic heart disease often progresses to heart failure due to persistent microvascular dysfunction that is not corrected by conventional epicardial revascularization.
Does topical transplantation of EPC-SMC-based vascular organoids improve cardiac function and promote microvascular regeneration in a porcine model of ischemic cardiomyopathy?
Does topical transplantation of EPC-SMC-based vascular organoids improve cardiac function and promote microvascular regeneration in a porcine model of ischemic cardiomyopathy?
Topical application of scaffold-free EPC-SMC vascular organoids preserved left ventricular ejection fraction and promoted microvascular remodeling in a preclinical porcine model of ischemic cardiomyopathy.
Should not yet change clinical practice in ischemic heart disease; hypothesis-generating for vascular organoid therapy and requires human trials.
Ischemic heart disease (IHD) often progresses to heart failure due to persistent microvascular dysfunction not corrected by conventional epicardial revascularization. We developed a scaffold-free vascular organoid composed of human endothelial progenitor cells (EPCs) and mesenchymal stem cell-derived smooth muscle cells (SMCs) and evaluated its therapeutic potential in a porcine IHD model. Fourteen days after ischemia induction, bilayer EPC-SMC organoids were transplanted onto the left ventricular surface, and animals were followed for four weeks. Cardiac MRI demonstrated the preservation of left ventricular ejection fraction and modest improvement in regional function compared with controls. Histological and immunohistochemical analyses revealed the migration of transplanted cells into host myocardium, increased vascular density, and enhanced vessel maturation, while gene expression profiling showed the upregulation of angiogenesis-related genes. These findings demonstrate that scaffold-free EPC-SMC vascular organoids can engraft, promote microvascular remodeling, and preserve cardiac function after ischemic injury.
No takes yet. Share an insight, caveat, or question.
Farag et al. (2026) studied Ischemic heart disease (porcine model) (n=14). Scaffold-free EPC-SMC vascular organoids vs. TISSEEL fibrin sealant only was evaluated on Left ventricular ejection fraction (LVEF) at post-IRI day 42 (p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: